This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

9 Meters Biopharma Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Bethany Sensenig

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage	35.7%
CEO tenure	1.5yrs
CEO ownership	0.2%
Management average tenure	no data
Board average tenure	2.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bethany Sensenig's remuneration changed compared to 9 Meters Biopharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2023	n/a	n/a	-US$46m
Dec 31 2022	US$1m	US$457k	-US$44m

Compensation vs Market: Bethany's total compensation ($USD1.28M) is above average for companies of similar size in the German market ($USD457.20K).

Compensation vs Earnings: Insufficient data to compare Bethany's compensation with company performance.

CEO

Bethany Sensenig (47 yo)

1.5yrs

Tenure

US$1,279,586

Compensation

Ms. Bethany Sensenig MBA, CMA, serves as Interim Chief Executive Officer of 9 Meters Biopharma, Inc. since May 30, 2023. She serves as a Chief Financial Officer at 9 Meters Biopharma, Inc. since January 15...

Board Members

Name	Position	Tenure	Compensation	Ownership
Lorin Johnson	Independent Director	5.5yrs	US$84.70k	0.057% € 4.5k
Mark Sirgo	Independent Chairman	3.3yrs	US$119.70k	0.57% € 46.0k
Mark Pimentel	Member of Scientific Advisory Board	2.9yrs	no data	no data
Michael Rice	Independent Director	2.4yrs	US$78.45k	0.027% € 2.2k
Michael Constantino	Independent Director	3.1yrs	US$82.20k	0.048% € 3.9k
Z. Falchuk	Member of Scientific Advisory Board	2.9yrs	no data	no data
Maureen Leonard	Member of Scientific Advisory Board	2.9yrs	no data	no data
Russel Cohen	Member of Scientific Advisory Board	2.9yrs	no data	no data
Benjamin Lebwohl	Member of Scientific Advisory Board	2.9yrs	no data	no data
Charles Randall	Member of Scientific Advisory Board	2.9yrs	no data	no data
Samantha Ventimiglia	Independent Director	1.8yrs	US$67.20k	0.027% € 2.2k

2.9yrs

Average Tenure

60yo

Average Age

Experienced Board: 2Q3A's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.

This company listing is no longer active

9 Meters Biopharma Management

Management criteria checks 0/4

Key information

Recent management updates

9 Meters Biopharma, Inc. Appoints Bethany Sensenig as Interim CEO

9 Meters Biopharma, Inc. Announces the Resignation of John Temperato as President

High number of new and inexperienced directors

9 Meters Biopharma, Inc., Annual General Meeting, Jun 22, 2022

High number of new and inexperienced directors

President recently bought €50k worth of stock

Recent updates

9 Meters Biopharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Rule

9 Meters Biopharma, Inc. Appoints Bethany Sensenig as Interim CEO

9 Meters Biopharma, Inc. Announces the Resignation of John Temperato as President

9 Meters Biopharma, Inc. Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome

High number of new and inexperienced directors

9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma, Inc. announced that it expects to receive $70 million in funding

9 Meters Biopharma, Inc., Annual General Meeting, Jun 22, 2022

High number of new and inexperienced directors

President recently bought €50k worth of stock

9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac Disease

Independent Chairman recently bought €84k worth of stock

9 Meters Biopharma, Inc. Announces Initiation of Phase 2 Vibrant Study of Vurolenatide for Short Bowel Syndrome

9 Meters Biopharma, Inc. Announces Publication in Journal of Clinical Investigation Describing Successful Use of Larazotide for Treating Multisystem Inflammatory Syndrome in Children Resulting from Covid-19 Infection

9 Meters Biopharma, Inc. Receives USAN Approval to Use the Designated Nonproprietary Name Vurolenatide for Its Long-Acting GLP-1 Agonist for Short Bowel Syndrome

Forecast to breakeven in 2024

9 Meters Biopharma Hosting Key Opinion Leader Webinar on Short Bowel Syndrome and NM-002 Program Update

9 Meters Biopharma Inc Appoints Michael Rice as Board of Director

New 90-day high: €1.86

9 Meters Biopharma, Inc. Announces the Resignation of Nissim Darvish as Director

Independent Director has left the company

New 90-day high: €1.22

New 90-day high: €1.19

9 Meters Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $30.000001 million.

New 90-day high: €0.85

9 Meters Biopharma Announces Positive Preclinical Data for NM-102, a Gut Microbiome Modulator in an Immune Checkpoint Inhibitor Failure Model

Independent Chairman recently bought €81k worth of stock

New 90-day high - €0.74

Innovate Biopharmaceuticals, Inc. (NasdaqCM:INNT) completed the acquisition of RDD Pharma, Ltd. from OrbiMed Israel Partners managed by OrbiMed Advisors, L.L.C. and others.

9 Meters Biopharma, Inc.(NasdaqCM:NMTR) dropped from Russell Microcap Index

CEO Compensation Analysis

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age